Skip to content
This website uses cookies to help us understand the way visitors use our website. We can't identify you with them and we don't share the data with anyone else. If you click Reject we will set a single cookie to remember your preference. Find out more in our privacy policy.

Navigation breadcrumbs

  1. Home
  2. Who we are
  3. Our leadership team
  4. Dr Chris Laing

Dr Chris Laing

Chief Executive Officer

As Chief Executive Officer of UCLPartners, Chris leads our work as a health innovation partnership and provides executive oversight of the NHS Innovation Accelerator, working with its co-directors.

He joined UCLPartners in October 2021, initially as Director of our Health Innovation Network and National Director of the NHS Innovation Accelerator, before being appointed as UCLPartners Chief Executive Officer in February 2022.

Chris undertook specialist training in nephrology, critical care and internal medicine, and continues to practise as a consultant nephrologist at University College London and Royal Free Hospitals, where he is also Honorary Associate Professor of Nephrology at the UCL Centre for Nephrology.

He undertook research training in renal disease, genetics and physiology at UCL and INSERM Paris. He remained active in research through clinical trials, health services research and the use of artificial intelligence in predicting acute renal disease. 

Previous leadership roles have included Training Director, Clinical Lead for Nephrology and Associate Medical Director of Royal Free London NHS Foundation Trust. He worked for four years as Divisional Director of Emergency Services in University College London Hospitals where he oversaw the acute care pathway, leading an extensive programme of transformation. In the latter role he also led the UCLH emergency care response during the COVID-19 pandemic. He founded and led London Acute Kidney Injury Network. 

Chris has a strong interest in digital health, technology and data science and worked for five years as a senior clinical advisor to DeepMind and Google Health.